HHS and FDA Submit an Interim Access Policy for Compounding Using Certain Peptides to the White House for Review

On October 14, 2026, the Department of Health and Human Services and the FDA submitted a document titled Interim Access Policy for Compounding Using Certain Peptides to the Office of Management and Budget for regulatory review. The OMB review record lists the regulation identifier number as RIN 0910-ZD94 and shows the received date as October 14, 2026. That submission, its title, and its review status are the confirmed facts in this post.

The submission authorized nothing and changed no rule. The policy was not issued on October 14, it did not add any peptide to the 503A bulks list, and it did not authorize any compounding. A document under OMB review is a step in a review process, not a published FDA policy.

Anything beyond the submission itself is reporting, and it is framed that way here. Reuters reported the submission on October 15, 2026, and the Associated Press also reported it in the days that followed.

AP reported, citing people familiar with the matter, that the policy could temporarily allow qualified compounding pharmacies to make certain peptides, including BPC-157, under an enforcement-discretion approach. Since AP attributed that description to unnamed sources familiar with the matter and the policy text had not been published as of late October 2026, that description is unconfirmed reporting, not FDA policy.

Readers should distinguish between the two records. The OMB record confirms that a document with that title entered regulatory review on October 14, 2026. What the document would do, if issued, cannot be stated as fact until the text is published through an official channel.